# Evonik: German Specialty Chemicals Company

> Research page on Evonik by OctumAI. Researched and written by GAR, Octum's research engine, from the public sources below; every figure is checked against its source automatically; this version was reviewed by Octum. First published 2026-10-30, updated 2026-10-30. Canonical: https://octum.ai/research/companies/evonik.html

## The question

What is Evonik: what does it do, how big is it and how is it doing, who owns and funds it, who runs it, and how do the company and the press describe it?

## GAR's answer

Evonik is a German multinational specialty chemicals company focusing on high-growth sectors, with Q1 2025 sales of €3,777 m.

## What we found

### What it does

Evonik is a multinational specialty chemicals company based in Germany. The firm focuses on high-growth sectors, particularly health, nutrition, resource efficiency, and globalization. It aims to provide customers with tailor-made products and solutions to offer a competitive advantage and improve people's lives. Evonik describes its approach as going beyond the boundaries of chemistry by combining innovative strength with leading technological expertise. In the area of resource efficiency and sustainability, Evonik offers leading membrane separation technology for biogas. As of 2026, the company partnered with Toyotsu Chemiplas Corporation and Sanyo Chemical Industries, Ltd. to develop a recycling model for polyurethane foam in Japan. This initiative aims to convert discarded foam into recycled polyols and amines for use in new polyurethane products. As of 2027, Evonik continued its sustainability initiatives by transitioning to 100 percent renewable electricity for the epoxy curing agent production plants operated by its Crosslinkers business line. Regarding health and nutrition, Evonik has introduced several specialized products. As of 2026, the company launched new, stiffer VESTAKEEP® PEEK dental grades to widen the possibilities of dental applications for PEEK-based materials. In the same year, Evonik expanded its ruminant portfolio with the launch of Lypron®, a rumen-protected lysine solution designed to deliver targeted amino acid nutrition and support efficient, balanced feeding strategies in modern livestock production. The company also advanced sustainable oral drug delivery through ambitious climate targets, life cycle assessment data, and innovative excipients. In the field of electric mobility, Evonik promotes the use of its additive AEROXIDE®. As of 2026, this specialty solution was highlighted for making lithium-ion batteries for electric vehicles more powerful and safer. Additionally, as of 2027, Evonik expanded its portfolio of epoxy curing agents with the launch of Ancamine® 2875. [2] [11] [12] [13] [14]

### The numbers

As of May 8, 2026, Evonik reported Q1 2026 sales of €3,427 m, a decrease from Q1 2025 sales of €3,777 m. For the same period in 2025, adjusted EBITDA stood at €560 m, while Q1 2026 adjusted EBIT was €235 m, down from €309 m in Q1 2025. The company also reported Q2 2026 adjusted EBITDA of €550 m. Full-year 2025 adjusted EBITDA was €1.9 bn. Regarding workforce size, Evonik Group had 31,000 employees as of October 30, 2026. This figure is consistent with data from October 29, 2026, which also listed the employee count at 31,000. A separate source dated October 19, 2026, cited annual revenue of $500 million. [1] [2] [15]

| Metric (May 8, 2026) | Value |
|---|---|
| Q1 2026 sales | €3,427 m [1] |
| Q1 2025 sales | €3,777 m [1] |
| Q1 2025 adj. EBITDA | €560 m [1] |
| Q2 2026 adj. EBITDA | €550 m [1] |
| Q1 2026 adj. EBIT | €235 m [1] |
| Q1 2025 adj. EBIT | €309 m [1] |
| FY 2025 adj. EBITDA | €1.9 bn [1] |

### Funding and ownership

In 2020, Evonik acquired Synoste for nearly $12m in funding. The company was founded by Theodor Goldschmidt. As of 2025, Evonik employed a workforce of 31,000. [14] [16]

### Who runs it

As of 2030, Christian Kullmann serves as the Chief Executive Officer of Evonik, according to Indian Chemical News. In the same year, Michael Rauch holds the position of Chief Financial Officer, as reported by the same source. The company’s leadership team also includes Lauren Kjeldsen, who is identified as the Chief Operating Officer for Custom Solutions on Evonik’s official website. Additionally, Dr. Claus Rettig serves as the Deputy Chairman of the Executive Board, a role listed on the company’s site. These individuals form part of the senior management structure guiding the organization’s operations and strategic direction during this period. [17] [18]

### What the press says

In late October 2026, press reports detailed BASF’s acquisition offer for Evonik. Sources dated 28 and 30 October 2026 described the total offer as €11 billion, while a report dated 29 October 2026 cited a total cash bid of €11.2 billion. On 29 October 2026, Evonik’s share price closed at €21.16. Earlier in the month, the stock price was EUR 21.32 on 27 October 2026 and EUR 21.19 in pre-market trading on 28 October 2026. A separate entry dated 4 August 2027 listed the price as EUR 0.13. BASF’s CEO viewed a tie-up with Evonik as a sensible step, whereas Dennis Radtke warned that a sale risked the loss of thousands of jobs and called for the plan to be abandoned. North Rhine-Westphalia’s economy minister, Mona Neubaur, opposed the takeover in the state parliament on 14 October 2026, where lawmakers also rejected an SPD motion for a state stake review. Evonik scheduled its Q3 2026 quarterly statement for 3 November 2026. The company also launched Lypron, a rumen-stable lysine solution for ruminants, with Sipena as the exclusive manufacturer, and began a recycling initiative in Japan with Toyotsu Chemiplas and Sanyo Chemical to recover polyurethane foam. [6] [7] [8] [9] [10]

### What the company says

Evonik reported sales of €14.1 billion for 2025, down from €15.2 billion in 2024. The company’s adjusted EBITDA for 2025 was €1.874 billion, compared to €2.065 billion in 2024. According to a source dated March 1, 2025, the adjusted EBITDA margin rose from 10.8 percent in 2024 to 13.6 percent in 2025. As of 2026, Evonik employs approximately 31,000 people. The company’s stated motivation is to provide customers with a decisive competitive advantage through tailor-made products and solutions, thereby improving people's lives. For 2026, Evonik projects an adjusted EBITDA between €1.7 and €2.0 billion. The annual shareholder distribution for 2026 is expected to be between 40 and 60 percent of adjusted net income. The dividend for 2025 was €1.00 per share, following a previous annual dividend of €1.17 per share. In July 2026, the company announced a US$100 million investment in a U.S. drug substance contract manufacturing site. [2] [3] [4] [5] [19] [20] [21]

| Metric (2025) | Value |
|---|---|
| sales for 2025 | €14.1 billion [3] |
| number of employees | 31,000 [4] |
| sales in 2025 | €14.1 billion [4] |
| dividend for 2025 | €1.00 per share [4] |

## Where the sources disagree

- Sources disagree on the company's employee count, with one citing 31,000 and another citing 34,000. [2] [19]

## Analysis

Evonik is a German multinational specialty chemicals company that employs approximately 31,000 people and focuses on high-growth sectors such as health, nutrition, and resource efficiency. [2] [11]

The company reported full-year 2025 sales of €14.1 billion and an adjusted EBITDA of €1.874 billion, representing a 13.6% adjusted EBITDA margin. [3] [5]

BASF has proposed a total cash bid of €11.2 billion to acquire Evonik, a move that has drawn opposition from North Rhine-Westphalia's economy minister and warnings about potential job losses. [9] [10]

Evonik is expanding its product portfolio with new launches, including Lypron for ruminant nutrition, VESTAKEEP PEEK grades for dental applications, and AEROXIDE additives for lithium-ion batteries. [2]

Evonik's leadership team includes CEO Christian Kullmann and CFO Michael Rauch, and the company plans an annual shareholder distribution for 2026 between 40 and 60 percent of adjusted net income. [4] [17]

## Strengths and concerns

**Strengths**

- Evonik maintains a stable adjusted EBITDA margin of 13.6% in 2025, indicating consistent profitability relative to its €14.1 billion in sales. [3] [5]
- The company is expanding its product portfolio into high-growth sectors such as electric mobility and sustainable agriculture with new launches like AEROXIDE® and Lypron®. [2]
- Evonik is advancing its sustainability profile by transitioning its epoxy curing agent production plants to 100 percent renewable electricity. [13]
- The company is investing US$100 million in a U.S. drug substance contract manufacturing site, signaling a commitment to expanding its pharmaceutical capabilities. [21]

**Concerns**

- Evonik's sales declined year-over-year, dropping from €3,777 million in Q1 2025 to €3,427 million in Q1 2026, indicating a contraction in top-line revenue. [1]
- The company's adjusted EBIT fell from €309 million in Q1 2025 to €235 million in Q1 2026, signaling a significant reduction in operating profitability. [1]
- Full-year adjusted EBITDA decreased from €2.065 billion in 2024 to €1.874 billion in 2025, reflecting a downward trend in earnings before interest, taxes, depreciation, and amortization. [3] [5]
- The dividend per share was cut from €1.17 to €1.00 for 2025, representing a reduction in returns to shareholders. [4]
- Political opposition to the potential acquisition by BASF, including warnings from North Rhine-Westphalia's economy minister about job losses, creates regulatory and social risk for the company's strategic future. [9] [10]

## Sources

11. Evonik - Company Profile and News | OLED-Info — https://www.oled-info.com/evonik
14. About Evonik — https://www.evonik.com/en/company/about-evonik.html
17. Evonik CEO Christian Kullmann to stay on until 2030 — https://www.indianchemicalnews.com/people/evonik-ceo-christian-kullmann-to-stay-on-until-2030-30082
18. Executive Board — https://www.evonik.com/en/company/executive-board.html
